Blueprint Medicines (BPMC)

Jeff Albers CEO
Mike Landsittel CFO
Christy Rossi CCO
Fouad Namouni President, R&D
Becker Hewes CMO
Kristin Hodous IR
Andrea Tan Goldman Sachs
Reni Benjamin JMP Securities
Dane Leone Raymond James
Marc Frahm Cowen and Company
Andrew Berens SVB Leerink
Avatar Jones Morgan Stanley
Arlinda Lee Canaccord Genuity Inc.
Paul Jeng Guggenheim Securities
Benjamin Kallo Robert W. Baird
Peter Lawson Barclays
David Nierengarten Wedbush Securities
Brad Canino Stifel Financial Corp.
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.

Good morning. My name is Maxine, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines’ 3Q 2021 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. Instructions]. [Operator you. Thank Blueprint of may your begin Kristin Medicines, conference. Hodous you

Kristin Hodous

This Good Thank and welcome Call. plan a to morning topics to outlines operator. release, Operating we which press Blueprint Conference discuss Financial and we XXXX everyone, you, the issued Quarter Medicines’ Results today. morning, Third

our website Fouad release, Officer, call, well by results. Investors the Becker Commercial recent going the also access Executive and at And third Today growing a update. will that our pipeline. on financial slides President and Chief will our Development, on www.Blueprintmedicines.com. quarter can Albers, Landsittel, call discuss available XXXX will across Officer, and highlights. review You clinical for Third as Chief our we'll Officer, will review our commercial the Mike our Medical is Jeff to XXXX the section press our provide Quarter Chief as Q&A. be Christy Financial Blueprint of be today, Officer, highlight Namouni, of reviewing Hewes, our Research Rossi, Medicines' progress, upcoming Chief our will milestones business

set various forward-looking results uncertainties, on expressed would we statements our SEC Actual make Before remind in risks, factors, will by any Risk this forth implied those statements. or filings. the a could or include of everyone and conference as I to events differ result we materially call, Factors those that section get like started, from including statements, of forward-looking other

representing forward-looking not update statement any We any of only or be forward-looking specifically of to disclaim upon this views as revise subsequent as views as addition, represents and made call, any on our date. any statements. should our obligation relied today In

Jeff Now, Albers. here's CEO, our

Jeff Albers

to three of the Kristin, quarter, therapies made good fundamental hear our about Today call, we progress third In joining and today. areas life-changing everyone, toward precision around on for our patients the you'll bringing Thanks, tremendous thanks us world. and morning, growth.

broad solid prescribers in is we both foundation for advanced topline of different KIT a across and by study for subtypes. provides mastocytosis academic in non-advanced first development demand with momentum our This inhibitor. from performance commercial anchored systemic and AYVAKIT’s systemic deliver seeing at patients centers, SM franchise, generation advanced from data of as continued launch leadership The We're US. the mid-XXXX, Pioneer to and pivotal AYVAKIT our next look SM BLU-XXX, growth in and mastocytosis our community accelerate

precision The of pipeline around is robust and of second with at all execution stages development. of continued a of based therapies the innovative growth area R&D advancing vision, expansion our

As Fouad been will initiate trial of describe, encouraged We've trial in X a wave proof of quarter. concept BLU-XXX, of on progressing clinical our towards multiple track interest in is our widespread readouts. BLU-XXX the Phase we're for next by fourth to SYMPHONY and programs rapidly

invest EGFR current which third domains, enables Mike drive to value programs, continue revenue capabilities. of R&D will CDKX clinical our and is our as integrated class us with strength MAPXKX to world and our we more multiple a a of inhibitor, into across a in describe area And to BLU-XXX, detail, company Beyond franchise, in inhibitor, advance next year. range financial continue expect development global BLU-XXX, position, growth high build to our

to into to and both our able throughout that, bring to medicine This across I'll years external well truly in come. the independently-driven, strategic in coming the over leading scientific view, positioned discuss some streams we're as increase to precision organizational diversity For our year Christy full portfolio, guidance prolific based our of revenue execution, now talked for of collaborations. our financial the time, Blueprint Combining we're our platform through commercial for about strategic call is we've diverse efforts. on business. pillars innovation driver revenue to promise activity Christy? our with and and the With to be commercial of turn assets, the strength

Christy Rossi

Thanks Jeff. Good morning, everyone.

Let quarter by me sharing results. start our third

AYVAKIT reported for and the sales Net by $XX.X of user $X.X Our GAVRETO, million as were product million. Roche, quarter. was net revenue

GAVRETO As to QX beginning a reminder, Roche and our US the opportunity quarter. full seeing, that booking trends view sales non-advanced of reinforce advanced disease, the was advanced the significant systemic early the mastocytosis, AYVAKIT of the of shifted positive at of first in near quarter we are have the at forms the Blueprint pursuing and Medicines. across term our SM that most we is been launch

theme gives launch to breadth a breadth, dynamics of is confidence and As date, prescribers, accounts, types. that I the me on key reflect patient

the with prescriber account breadth start activity. and of Let's

with As accounts previously, engaging I've shared been concentrated. key patients excellence area of SM has for and focus Blueprint, where are centers a more key

the of our now two approximately thirds few good the Over first commercially. to have efforts these centers launch, months with traction, engage gained AYVAKIT utilizing

cared our therapy. are half accounts that prescribers they volume AYVAKIT setting, have have As a to advanced first time SM catalyze the prescriber I'm This approval community very and identification our focus continue identify coming end community of ongoing in will accounts. and and we of mind, we of prescribers we education know SM. Overall, efforts that in more the prescriber AYVAKIT that long had for for more XXX that from there, through be or is also since critical encouraged to than With and utilizing launch. to the will access many patient trajectory in our patients term to here, patients, new breadth QX, advanced the ensure approximately

SM patients across AYVAKIT of also treatment are We breadth their advanced by seeing journey. utilization

those mix We prior therapies, therapy. SM continue other have advanced switching from patients who no indication even a and fairly a of of see to

into advanced these dynamics but as prevalent suggests patient pool used newly launch, of being We among move we as early additional in patients, is patients. diagnosed gain insight the AYVAKIT that will through as incident SM data well this diagnosed the

has to prescriptions. rapid total, our In we supported based form seeing, growth. we of term the combination for and expect new patient foundation Finally, this by trial breadths, the revenue a long account are therapy durations strong increasing and therapy, a to on of longer demand access been experience, we fill are time prescriber starts, patient clinical pleased and that

blood-based launches to course, for I'm to SM we position who our can ongoing on continue testing, building year, our broadly. our launch about identification testing leadership I'm progress increase for testing A Testing across we've SM improved and rate make We availability available SM patients DXXXV program important as look to plan to the this of offered in States. the about in quarter key transform accessible BLU-XXX. improve an opportunity next global development SM, the and we've Overall, non-advanced advanced continue a partnership and diagnosis diagnosed patients third and SM, United access more treatment. made steps critical suspected. available so and of goal. initiated in for KIT on PIONEER we are see the in sensitive is now which the widely launch our globally. ahead of We've from the disease patients we patients. that patients of on realizing LabCorp focused US to quarter we SM, advanced is the access is readout patient be diagnosis execute that and anticipate appropriate execute in also more to As excited the is this testing, education road help to to widespread with qualifying are achieve through very of AYVAKIT in facilitate suffering priority excited and increasing to highly the care care taken will to for to where potential US, SM, the sponsor towards

now GAVRETO. to Let me turn

the our our Roche patients we market Genentech, it mentioned, bolstered on globally. we where We fruition. enhanced the our saw that to of the on we've focus reach QX, treatment-naïve to actionable begin see was through and comprehensive pleased we with As We're this momentum coming patient collaboration continued key ability rationale In a shared strategic were at expanding ARROW US, during more strong red to ASCO, the testing continue by data growth efforts excited updated to biomarker come diagnosis. from inhibitor and to rates with increasing study. for out

provides is Roche strong we partners like GAVRETO would in for to review to quarter, that non-small cell GAVRETO indication in cancer approval EU the a lung setting. our the in global roadmap for agnostic the clinical Fouad competitive to combined over launch An that, for the CHMP ongoing territory opinion line a clear this in third pursuing a by This, I additional in regulatory GAVRETO. received the During applications with of revenue positive portfolio. call With China advantage planned CStone, would growth. also be a multiple at now turn geographies, our and

Fouad Namouni

and R&D Christy, Blueprint Thanks, across three the trial today bring scientific platform. on world's to update Earlier including area progress faster, team near to the focus, precision mastocytosis strategies, development, the our innovative this excited as oncology vision productivity use expansion the leadership I'm of realizing Medicines research areas our good good made leadership that creative included data, focus portfolio. lung has and a vision therapeutic drug of I designs, position term regulatory R&D This patients cancer, therapies the and morning, with and and shared towards precision on in to leading translational year, the you hematology, with our of everyone. and through continue therapy systemic company. very to our broad the

leadership through robust our we KIT expand systemic in our continue to programs. mastocytosis of First, execution

registration the on next of non-advanced in our directed topline year. AYVAKIT, middle to PIONEER is SM, in deliver For results study track

Phase screening inhibitor, underway. began third also carrying momentum For HARBOR X, forward portion systemic in now In we BLU-XXX, down the X patient wind PIONEER KIT of mastocytosis, X our as we non-advanced in quarter, next enrollment. the study, generation Phase study, the the is

patients including with all advanced As the with SM, us SM, the in is launch commercial these dramatically of population AYVAKIT improve across standard disease. of with a enrolling reminder, of of forms forms non-advanced of to encouraging care milder position Combined broad systemic HARBOR studies the a patients mastocytosis.

advanced in we lung Second, significantly program positive cancer. our have clinical EGFR

significant in trial sites. enrollment is accelerating, with patients multiple growing and demand BLU-XXX, clinical the For at SYMPHONY

patient generation As populations. such are across our osimertinib expansion with next This multiple phase the will is extend of accelerate we study the as effort escalation dose EGFR development moving planning now third inhibitors, rapidly, approach and year. combination

trials footprint happy we the important place We EGFR This robust therapies report trial expanded an for with agreement trial are a also now Asia. a towards global scope, milestone our clinical building represents to for in Japan. of that in

continued For application are including explore to to support plan and Similar combination have on data a X, submitted track we to study, this fourth BLU-XXX, development X study, early the to clinical development study FDA, to we BLU-XXX. Phase our strategy. the quarter. in initiate an SYMPHONY we I&D Furthermore, the with pre-clinical in

have early scientific and are on completed the studies at data generating recently a meeting potential We submitting XXXX. which for in of we compelling combination, a BLU-XXX BLU-XXX presentation

we targets, further with the XXXX, These programs flourish. enter early the expected. in More stage work, have earlier of BLU-XXX, leadership CDKX oncology our and recent our year. than undisclosed scientific research number first pipeline also it and continues anticipate we broadly, will include to potential multiple In rapidly inhibitor to research our this now months, exciting progressed Finally, have through a extend in previously enabling precision hematology. quarter I&D nominated selective clinic the we of

to Mike research, turn Mike. these to therapeutic sharing to on As through of programs another look candidates. like wave discovery financial more forward updates. information discuss would I it to over we now progress

Mike Landsittel

financial press Thanks, release. in we Fouad. morning, quarter detailed results this third reported Earlier our

on today's fourth we of - the a strong into foundation strong Blueprint sources. I'll through touch our range as on financial continues quarter, few a foundation highlights But For quarter. first, the build head call, to revenue from

between we contribute In growing the quarter CStone third sales $XX.X of China. as million, and expected into including In fourth from increased sales, revenues our Roche, for revenues driven is annual including the quarter multiple our guidance million the the and and across base AYVAKIT of commercial partners, fourth in $XXX for of milestone anticipated CStone milestone acceleration AYVAKIT, net of AYVAKIT revenues. revenue. collaboration meaningfully raising in well potential are addition to million as strategic quarter, our to $XX.X supply $X.X collaboration other achievements million XXXX to GAVRETO global and to revenues progress $XXX collaborations from Based revenue for by payments, on our of Collaboration our GAVRETO sales and quarter, primarily and royalty revenue by was million. were shipments total product revenue to

our share our Roche, US appearing reminder, being sales income or a now on As loss with statement. GAVRETO of booked are profit by

Our total in operating expenses into programs expenses, slightly XXXX, continued multiple increased growth we development. as clinical to compared R&D driven quarter third quarter in bring the by second the of

as next our our commercial Over operating SM, in as quarters, AYVAKIT launch quarter-over-quarter the few we early that continue advanced in investment programs, the promising with well stage of expense anticipate ongoing efforts growth. will

focus strong financial nearly position, portfolio over Finally, on we operator this operator turn revenues company. transformative billion we ensuring the have call to our with to fortifies enter quarter pipeline. collaborations, $X.X progress third growing period as allowing the our to us invest growth like our questions I for across another through in product the to execution of we ended on of combination sufficient our cash would now Overall, in the exceptionally resources hand, and for


Goldman Richter Salveen [Operator first Instructions] Sachs. Our from that comes question from

is Your now line open.

Andrea Tan

This on for the quarter. Christy, on is a question everyone. Andrea the for Hi, maybe question. for Congratulations taking Salveen. Thanks you.

speak more addressable expand if with and on these quickly, expect then bit this LabCorp of And any patients partnership potential if your at the how excellence. Just centers could wondering in very you utilization you you're population. a non-advanced seeing to

Christy Rossi


we're this patients, for building before, blood-based strategic access Throughout highly year, And as been LabCorp. So, in the the US, believe DXXXV SM sensitive testing testing particularly partnership available discussed be has that will patients I've making KIT with and key facilitate diagnosis ours. for blood-based non-advanced greatly about where excited a may of to diagnosis focus we quite suspected. capability

LabCorp LabCorp, available commercially. this with testing partnership the so, And has

very who LabCorp prescribers use helpful and in be for of nationally. itself, that, will So,

We having Blueprint. we a through suspected where sponsored if is of will a they that available patient diagnosis, a have have program receive can SM - is to testing an testing access

so SM, will also we the type testing, patients results barriers reduce suspects that believe appropriate the for get of they a that and this provider if ensure the utilize And can that and testing to so, potential that trusted. they hurdles be access

step really forward. this about as a we're excited so, And

on And In terms said by to are patients, and certainly is as but who have best patients of perfect visibility SM we our diagnosis don't speaking We, say to intelligence now, are patient. course, the right continues that utilization understanding be SM subtyping the the I of being prescribed before, into complex, to least, in and based every have AYVAKIT, healthcare large. that's providers. understanding our advanced of from

Andrea Tan

Great. Thanks so much.


Securities. from JMP comes question next from Our Reni Benjamin

Your line is now open.

Reni Benjamin

enrollment calculations questions, and give too by on revenues? terms give meet Hey, thanks required, this PIONEER us study I quarter. And GIST the can but you had calculation guys much. if just to very a that's not the to an for TAPESTRY is a I'm great third at off a quarter, think taking deadline, I might also enrollment our completed follow-up have think Because and sure. maybe just have Thanks least the I SM of congratulations breakdown update on Can here. completed? in would versus in the us KIT of you and the

Jeff Albers


the why half? take half, the you take So, and first Becker, second Christy, don't

Christy Rossi

terms a do historically seen, breakdown as obviously of provide formal as we consistent say, I has you this been, stream we've look of you've of in Blueprint GIST point. but terms indication discussed, revenue, and So, would split, not if relatively in at revenue for kind

key international of quarter-on-quarter SM little so, from if on well quarter-on-quarter And as driver, really really at look coming is growth, look as advanced bit primarily, SM as advanced but when growth, a it's we you well, the

Becker Hewes

and enthusiastic multiple two we to respect again, to interest there study, are then With mentioned tumor PFS of in that transitioning with actually make patients have - sure Roche, study. the trials, we're pre-screening. this the processes to And severity continues the on score call, types you mentioned with to TAPESTRY, in PIONEER, the getting screen right disease the enrolled the as respect to patients last and I into stopped the be we've

we to the the filled enrolled of forward year. we're so, in our of patients revealing converting looking topline in we study, middle And and group and into next data screening those patients, are

Reni Benjamin

Thanks taking the for it. Got question.

Becker Hewes

shifting also really HARBOR I this BLU-XXX. list. enthusiastic that generation KIT next to mention over more momentum more - a treatment. extensive and lot interest site into We the moving I'll about we're want inhibitor taking that we're discovered an it just to has and even trial The also

Reni Benjamin

you. Thank Great.


next from Dane Our question. James. your question with proceed Leone from Raymond comes Please

Dane Leone

you taking Thank for the for to Hi. keep two questions. I'll it me.

at that Firstly, X could terms does in this seen point, and TXXXM I of us with have you the comment all the that mutation. do at Anecdotal treatment? most of evidence a not progress Phase in mix suggest patients do enrollment have you're getting a BLU-XXX think

the and the treated secondly treatment therapeutic of little around do now could study, TXXXM. that to getting and a open, around implications that kind getting qualify rate treatment in treated for the So, where index into over just you and evaluation Thank be percentage of those would trying get dose for XXXX. ASM effective those of bit think just hurdles that patients about then center terms for your for with utilization of thoughts And to me, avapritinib, drug the you. being of to patients utilization ascending docs of maybe patients now. increase going what's and complexion the curious centers be now the in some the more the your that you heading are team's comment for

Jeff Albers

All right.

take So, XXX can Fouad, why necessary. the Becker color add study question, as don't and you

Fouad Namouni

Thank you, Dane.

phase. X, - progressing very in really the seen in in is a momentum. we Phase XXX dose months For way the with good the are escalation have have And happy we four the SYMPHONY it trial, we

CT the to pick CS allow in And better a mutation, XXX, and and signals. of and months be information. tumor next is much to detection the able of would mutation, use of the mutation, DNA, very to We all are understanding mutation, double variety with of see of really mutation, safety also profile, clinical have triple profile on a happy our that the TM by investigator us also this able

will We next part be first XXX. the on data of year sharing

Jeff Albers

in seeing Christy, the you And of we're don't activity ASM? take right. where All breakdown

Christy Rossi


beyond So, I well forward think going opportunity centers, I your think, question additional opportunity speaks sort at of the is as in as terms of to, what that.

centers is said, amount by significant of be a got see and had of community. happy So, the coming accounts the of also pleased engagement we've accounts very excellence, to consider I accounts which of utilization we're sort utilization we to that that I'm two of in in thirds we've that as great. those But key outside

I think accounts. there is additional key within opportunity

I interesting that about is ways. what's market think it an is in SM still many immature

specialist see And one center SM other in be to may that we so, diseases by where at is a patients may funneled tends center, that person, every that patient these have what at unlike maybe multiple you a to have providers. seen advanced

see to term, trend data continue growth of out been seeing. we really and one focus getting are be to educate us again, really also so, additional within forward that see and community we're Certainly starting to one as forward. that have we're But forward interested utilizing watching And the tale a and what as where given think at something gets patients going to with on catalysts go of identification there. identify prescriber that key we're going that looking more continue I we for additional to patients is happy is our out that deepening that having long I've patient and will into presenting, account we more driver and And to than accounts AYVAKIT. the

Dane Leone

Thank you.


Cowen. And Marc question the from from Frahm comes next

now line open. Your is

Marc Frahm

things and just Hey, in the have And the community-based Hi. just my just the the these that different types on or you follow to with in cohorts expansion to are when then then physician seeing who use just up CXXXS for congrats the enrolling have oncologists, ultimately you in - about the than allergist broader really questions seeing use to focus? CXXXS broader Thanks question and on last that also expect XXX, or are and some are points that that places they their of community, of other like you are, on populations follow within for practice? up and taking is quarter. office use than mutations, Dane's may on or patients resistance still other is Christy, some like ASM would main

Christy Rossi


So, your can I start with first question.

of whether prescriber is mix that now the vast center hematology, that's of community. excellence types utilization of right majority coming seeing, terms in in we're or the So, of at from a the

by utilization some allergy. seen have We

allergists point in often I patients, management think patients, important keep role a that certainly SM with a hematologists. in in co-managing be is these the for and to pathway are the many of diagnosis what's in will critical involved patients to advanced mind play and of

coming the hematology we've this so, at And seen some allergy, from point. majority again, from utilization but vast coming

Fouad Namouni

for XXX, X of And SYMPHONY to mutant triple Phase and the drivers second trial CXXXS. is also your for agent TXXXM all mutations. the with XXX is covers our expand The question, in Marc, way subgroups was designed

mutation. triple and expanding in So, TM mutation. double in we'll We’ll expanding CS double be in be also mutation

we'll understanding So, mutations. very of of spectrum really these broad across have a a good combinations

Becker Hewes

I one Marc, with XXX a is is the just optimized to large add to wanted mutation, but hit the really winded compound triple wild-type. a compound it thing.

to And into compound, we're of these safety. safe given be. really molecules earlier open and it for plays to we therapy. combine So, extraordinary how activity plan to move we of expect expect all just That levels lines our really this to

Marc Frahm

helpful. Very Thanks. Okay.


question Our Andrew from Berens from next comes SVB Leerink.

line is open. Your now

Andrew Berens


this quarter. my add execution also the great congratulations me on Let

on wondering I'm average from how previously had AYVAKIT sustainable. for how about patients how of the using program? had and percentage see Christy. they seem diagnosed? XX% translating a patients get missed of revenues. had prior question been color XX% few this me. the to rep again, the just or have quarters, you And be ago give that a then Were and hear the lines expanded the a long Just not to a you in I And access wanted for these a Do there GAVRETO guys in any therapy the market doesn't just didn't on I quarter in many really should patient seen new being Is percentage if you like sense meaningful that. it QX, for large? we saw is on trying that be excited to why starts to results QX of

Christy Rossi

are So, me. for I those all think

start with SM happy the color. to So,

the of certainly terms were dynamics patient in patients the through onto that in saw quarter, did coming patients on some prior. we So, have who programs the of the minority quarter. It's we access AYVAKIT

- think bolus? speaks approval. I patient from little I waiting is become your drug sort available the And certainly a patients waiting the question were of that excitement have to there commercially. well, your AYVAKIT bit for know think was were to, experience AYVAKIT a for that who centers is this of seen we've a frankly There and lot what

and the accounts we're to growth, and and offsetting we patients able think continuing to will that to approval. of of pull we pleased sort upon that offer and them board. be drive What certainly, on prescribers what on that is So, rate were treatment those continue now see new I come

And so, quarter. just that to prescribers breadth, about we've clip see excited through that and I'm pleased add indicator as accounts growth of potential, see steady really really a critical at I we've the continued prescribing. very new a again, of to the and moved as long-term

of who've patients indication say do as have they that therapy, we're a been therapy of not those now on said, of pretty who In suggests a right a that prior prior seeing terms terms lines versus our of even split data therapy. best in I

limited. Our mix we to have better think we own that visibility And right like. claims frankly, through exactly patients into see is start what that a we'll our looks sense, data, now as of

continue launch. we'll would through the insight I we to as gain so, that move And that say to

GAVRETO, to starts our through model the sort the individual question have think of than simply of of revenue? different sort a to with distribution They terms visibility do. about about level new of Genentech, is how we different. we So, do patient then transition In kind of and moving

in level the growth, our kind at date we're of had really, demand - quarter looking best this as prescriber of essentially now indicator so, And strongest to and QX.

about excited speaks patient ongoing And Lilly. that between or new market, I've both said the products, so, we're we're into which will Blueprint transitioning it of I as It and the new revenue. growth across to, time, think, before, take that seeing starts and

New share of growth which is will time. of really total indicator strong. to over translate revenue quarter-on-quarter share, be then continues And course, a revenue leading into our

Andrew Berens

you. Thank Okay.


Our next Avatar from Stanley. Jones Morgan from comes question

Your now open. line is

Avatar Jones

for Thank questions. taking this on And visibility will into Do question been have average you suspect how my to therapy any I you have Thank moving but Many you would date? answered, of forward, AYVAKIT. duration you. one have the evolve?

Christy Rossi


meaningful of duration of of that really this the too potential, think, - So, exciting a driver certainly impact point I it's living are exciting one have patients because it get think really further is a I the which of well launch, is have to any be may just also accumulating, therapy early I into the particularly months long growth, clinical launch We’re - therapy. advanced on and think At this with is point. right? really couple to and most it's duration SM of can SM, see opportunity. in is opportunity in I as therapy, the patients we advanced sort we Certainly, our how the aspects clinical of the because onto a critical stay will be of suggests AYVAKIT data a they few can think exciting, years. insight at into on that market for patients

year insight what what in to two terms the have through next go understand that over as think really so, And of better we'll we seeing we’re to I looks like.

Avatar Jones

Okay. Thank you.


Arlinda next Lee from Our Canaccord. comes question from

your proceed Please question. open. now is line with Your

Arlinda Lee

up you newly about and that provide an on might provide Congratulations follow maybe if already little be the that on breakdown what kinds tests Thanks. were who additional on the the - of information be guys. it patients the a those quarter the additional talk And might I Could on for you known. Hi LabCorp were said available? to maybe patients diagnosed color you be can you versus bit time eligible. turnaround and had able would launch. available that that additional of to

Christy Rossi


half So, we're that feedback prescribers of how patients again, really therapy being variety of we of saying that coming splits terms they right seeing, mix do about they’re of of not diagnosed. which now, other have we're is therapy a patients used. are from newly that understand does directly, the therapies prior versus saying prior relying that in and on hear indication from the not necessarily No mean we half

kind help will continue as as that other to sources to said, we to I inform insight will so, start our of gain understanding. And we see that data and claims

is Our move who incident are will diagnosed prevalent primarily expectation, the utilized being to newly patients from that we already diagnosed, in through as launch, we patients. shift certainly,

And a anticipate really we again, just know what we're I seeing. so, dynamic early too would that's but be, will to it's

the diagnosis. often test, a less that criteria, a eligibility I And symptoms the different terms of to order essentially fairly where potential turnaround In couple of hallmarks a of of one of the quick. it's form a time are we something is on out ask believe to have two or physicians the LabCorp fill than SM week. specify they

test. of to essentially is eligible SM order we're the be suspicion, in for for looking what So, clinical suspicion

Arlinda Lee

and you, again. Thank congratulations Great.


Schmidt The Guggenheim. next from from question comes Michael

Please open. Your ahead. line now is go

Paul Jeng

Thanks for Hi. on question. This for Michael. is taking our Paul

explored. thoughts one development, other X.X program. in with inhibition Just triple provide for to being like are potentially it approaches are included the DDA CDKX your on Can in instance that you us of from how on compare CDKX

see to landscape. read early Thanks. on your hoping there the Just

Jeff Albers

Becker don’t if needed? start add color can why maybe Fouad, So, you

Fouad Namouni

you. Thank

others. allows a inhibitor selective, in developing landscape, entire earlier, very is CCNEX, developed early inhibitor the CDKX, CDKX, a over over inhibitor faces next of with landscape entering look CDKX. to CDKX you at as selectivity profile. CDKX, one regulatory I to mentioned over favorable the and CDKX our selective CDKX, that year, has in When and clinic is efficacy one. validated is potentially the safety It a This target, selectivity also of the but particular Our challenges been partner as be leading CDKX

strategy sole CDKX/X. its CDKX that with selective believe with ability So, strategy good believe a we do profile, with that the is inhibitor of CDKX, us very for partner also gives combination our good doses developing to a CDKX/X. very We is different the combine a selective

cancers, strategy endometrial so targets addicted will of major be believe in driven diseases. the pathway, the with developed combination we where standard tumor CDKX areas, cancer, care ovarian two to and CCNE development Our that cancer,

emerging that of focus resistance cancer. breast the CDKX/X behind development breast We issue in to on CDKX part cancer. other know today is the to will CDKX/X resistance The in of the over-expression of CCNEX

looking the cancer, CDKX/X So, reverse in combining be not by to also resistance, in to stage. late breast we'll early in only the really but stage this contribute

Paul Jeng

you. Thank Great.


from Our next Joel Baird. question comes in Beatty

Your now open. line is

Benjamin Kallo

on for for one AYVAKIT, Kallo questions the Hello. This Two us, then one on Joel. Benjamin on and pipeline. is

AYVAKIT, a risk into prescriptions? as the As the have put or repeat it less and for risky than of maybe initiations then see relative the or if context do different not far you more others? could you. risky highly plan XXX. Do one XXX, XXX pipeline, Thank And the on as you you if of number sense, curious the missed I'm not, but I'm sure I just

Christy Rossi

them. Sure. can take This is Christy. I

one first repeat The on prescriptions.

on expect, of we in patients expect launch. that we're is that find on. their we than would that which any in often, is dose, right that know Certainly, going different We’ve nothing again, if seen to terms patients dynamic are the will would So, what refilling. be happens early be we early the do

to dose the so, occurring first be few modifications, in And et months. cetera, tend

et that. so everything flat far, continue we'll strategy that's would expect line really of a pricing, would we But watch, we we’re but lot seeing what mitigates cetera, with impact expect. see essentially to a that around trend in the from to Our

Jeff Albers

opportunity, terms success of the oncogenic We opportunity. yes, after concept take have programs in at the you I going as drivers quickly relative where in think of in priority of can look higher of or where start, though, be there question we our remains of terms all our always Fouad, the relative process. of portfolio I'll but our of well, get size into cases to it's as risk, possible, disease Then known a as selection a the of clinical should maybe hallmark we proof a Sure. do account probability

you but before take it's enter almost why Fouad, impossible don’t right a stab? clinic, So, an you the exercise,

Fouad Namouni

that CDKX. resistance point, to To a use weeks of cancer. months. Phase selective a for company, or now of has CDKX, taken broader are Obviously, Jeff's precision I treatment. against trials about molecules entering are the add, our or scope lung that as think like of as leading clinical to the we well-validated for next It's targets to answer Phase Blueprint designing in X a next it in mutated really thing either EGFR The important to example, cancer, these level is, targets whether studies medicine of rationally or expertise and only targets as Blueprint the would an these X with treatment one in are strongest breast the are opportunity, from cancer the would Jeff, you

it we development, determine windows as with efficiently, I when these of data tell the we development the I'm would confident with information see profile with compounds really we selectivity, that more of the or X. in this think with a compound, of and these us of we will responder indexes have the the very - agents. So, what But hypothesis from therapeutic run to part will Phase data

Jeff Albers

course with been with maybe molecules to develop a want of of And programs? our to we And combined it Operating Yes. that, Officer, has we Haviland, our therapies, be circle talks do can effective first how if back. cornerstone It's that programs change disease. Chief of get about idea really always Kate strategy other subsequent interesting. the wave often over better our I'll

program, window focus our combinations I'd see certainly of that's true noted of you activity, the expanding Similarly, could how part for over Becker XXX, the as the CDKX so, opportunity for that time. potential product earlier over target in be on say profile, on comes the was that various but that And a opportunity so wild-type to true single looking was that will we BLU-XXX, the agent full to combine reach time. you

critical the with see is we selectivity we move as hope about to that Fouad into really what BLU-XXX, to that so, And respect talked to clinic.

Benjamin Kallo

Got it. Thank you so much for those insights.


Peter The from Lawson Barclays. next question comes from

Your line now open. is

Peter Lawson

so taking question. the Thanks. Great. Thanks for much

there, thoughts number? a of of Just milestone driven? A thinking Should think And second out when out Mike, any exceeds and million breakout or is a number revenues or million is sort $XX revenues about quarter. just - of happened of a GIST break then way about milestone those Thank Just you'd any revenues? if ASM the where point your as $XX the ASM kind and kind this, this would you. question that break of rather for is guidance. much and or underlying that kind GIST the we you there How the there GIST

Jeff Albers


start. visibility every maybe So, into I'll We perfect don't patient. have

So, be of effort sits, of will the difficult. trying exactly them probably each out to break where

the So, Christy line think from is a mean, think maybe, as I that I it'll coming clearly … exactly we the be highlighted, data ASM. don't you already on I don't based then has degree And see, is, growth where But focus. Mike, that detail. we of have

Mike Landsittel


So, just color more on bit guidance. a little the revenue

the in like in we've $XX backtracking the potential now a milestone little also think guided that we've potential seen that are I And concentrating have fact that XXXX. to acceleration I’d might lot a forecast What year, recognized is we the for of million maybe a primarily but of were bit of seen we've includes early originally, payments. today, say, we - little potential QX. bit, in milestones what milestones that

by revenue the revenue as payments, to supply other we're those we fruition that as So, come and bulk of that guidance seeing royalty together the as payments, payments. QX, collaboration in and anticipated, raise milestone is come well driven

Jeff Albers

position, breadth I'll we on and patients collaboration either we've that. over in the I a our to therapies truly that expand focused have maybe payments payments, have user accelerate is to on - growth. we're That we with mix and bit what opportunity from of revenue underappreciated royalties, that's a growth, is in our milestone that's always looked is differentiating current now continue our place little at is our retaining to aspect an And also commercial or go reach. maybe add meaningful And to streams, But I mean, lumpier Yes. think as a other of bringing we partners. of rights own. going quarter-over-quarter, on forward. But and and revenue end revenue collaborations seeing exactly than as

which would to I continue my revenue comes long-term don't it research in from. meaningful So, to seat, say I drive is care going our allows where shareholder value. in platform, It’s us the and way invest really to the we're

Peter Lawson

Thanks for that.

patients to heme of ASM about eventually? the up for come Just on going from ASM. to side follow Christy’s comments the Are the or allergy majority

Christy Rossi

will to certainly be hematologists. That’s majority SM the specialty manage. that primarily Advanced of Yes. tends

involved. be can certainly allergy said, I As

be Sometimes advanced the they're for SM. to hematology involved primary continue but expect driver in we co-management, to

Peter Lawson


Okay. Thanks so much.


Nierengarten Our next David Wedbush. from question comes from

now Your is open. line

David Nierengarten

a death. taking that question. commercial for questions to thanks any often Hey, beaten skip I'll

therapy in the On XXX, goal. the out pipeline setting maybe and for line that if with could XXX Is to it XXX XXX second you and with us help say combination have ultimate a and a that's mutated clinic agent to from studies to we mutated entry what these into goal, ultimate your And cancer? do combo? need the - see with EGFR the accelerate Thanks. if single then lung

Fouad Namouni

combination agent, EGFR David. combination have in fourth our designed developed with a EGFR you, and generation mind, have fourth with in - Thank and XXX been XXX, mind. been

as allows of widest to that be XXX, Becker agents. only one selectivity wild-type but this profiles in EGFR. over developed mentioned compound, quickly, to the not other as very also agent, same And be a So, has combination developed earlier, with

earlier, CS year we'll penetrant, towards other be has single highly I generation third As more next agents. but starting highly combination XXX developed with on a driver and also on mutation, been XXX. mentioned developed with (indiscernible), potent agent, mutation, also as combinations EGFRs brain

both is able see of being displace treatment late EGFR lung cell combination our agents synergy profile in to and to of we developed terms the as to that's in of each stage. potential the move to on-target do agent care. of But two the combination positive and ultimate the frontline the standard like better And non-small goal combinability a agents, single would together these of because cancer. than and for So, in strategy,

at combination EGF, also looking these things. we but and It be addition mutant combination agents, others. talked lung four osimertinib, be generation will compounds. off-target RAS. when be treatment I could to EGFR inhibitor. with profile ready with to just such could in agents. it's a XXX, will It We can the of cancer. include selectivity looking, given chemotherapy I the become agents about that also and could and XXX in third-generation Off-target of of as be these the combination developed cell be It non-small believe of agents do transformational together, variety med could the other

David Nierengarten

the just into potentially open off-targets Thanks. how just XXX, I And is basket Thanks. it as curious might come? before, be broader study they going far other a those look maybe interpreting on quick guess, results the again, to and or agents. follow-up you to just on I'm Again, a focusing XXX,

Becker Hewes


to as combining mechanisms Becker. need this but action we're resistance, for combinations dosing agents in that. in take really I on of that going RAS we're So, agents, data inhibitors, tolerability broad targets initially is data get parallel. it our is an with and the as program single resistance With other with of a sequential respect development. we such to but I'll or have We these address the - studies, tend ongoing to see extent, to MAT potential and information don't in and resistance to this front fashion and other a let do where get emerging to things resistance adding pre-clinical for guide us or the our we'll quickly trying

David Nierengarten

it. Got Thanks.


today for from question Stifel. comes from Brad final Our Canino

line open. Your now is

Brad Canino

to by like we than something just like launch fitting that trial. to going for previously there MAT. Thanks TXXXM, the XXX. per mean, likely the And is other cohort, it execution on here. me gen looks again, more great not first in, the CXXXs. on but like go me talked cancer about to I on protocol, driven and they're and one Great. specifically for that OSI TXXXM, EGFR And call,

specific you to higher talking this be Thanks. monotherapy really about see, been the in expecting you've on window sparing, focus cohort? because and looking this the or is are cohort So, should therapeutic for XXX this safety and we efficacy wild-type

Becker Hewes

mean, and is focus the focus This study. safety Phase I obviously initial X, this is in of main the Becker.

TXXXM mutation it. very reminder, has However, will that just inhibit a on the strongly XXX protein any

is and EGFR or We seems more are EGFR more trying populations where look, of patients there patients heterogeneity driver. believe we are There this to multiple - be cancer. a cell. There the still more the have you understand case. the the within multiple or of the patients mutations even better And it's the protein primary heterogeneous where the we other cells single to that are drivers that

we as expect agent have biology, so, understand sense single to activity. the we'll And a better of where

we when emerging that an speak more later story have that's So, to we'll data.


With that, for I'll Mr. Albers hand call the remarks. back to closing

Jeff Albers

time And Operator, of today you thanks to support look you, Medicines. Blueprint for taking to all we to you all continued again join well. Thank hope and soon, and and us updating forward of you for your stay Goodbye.


and Ladies Thank gentlemen, this today's joining. call. for you concludes

disconnect may You lines. your now